118 related articles for article (PubMed ID: 38539560)
1. T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Absmaier-Kijak M; Iuliano C; Kaesler S; Biedermann T; Posch C; Brockow K
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539560
[TBL] [Abstract][Full Text] [Related]
2. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R; Zimmer L; Al-Matary Y; Kaptein P; Albrecht LJ; Shannan B; Brase JC; Gusenleitner D; Amaral T; Wyss N; Utikal J; Flatz L; Rambow F; Reinhardt HC; Dick J; Engel DR; Horn S; Ugurel S; Sondermann W; Livingstone E; Sucker A; Paschen A; Zhao F; Placke JM; Klose JM; Fendler WP; Thommen DS; Helfrich I; Schadendorf D; Roesch A
Nat Cancer; 2023 Sep; 4(9):1292-1308. PubMed ID: 37525015
[TBL] [Abstract][Full Text] [Related]
4. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
5. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features of imbalance between Th1 and Th22 cells and its association with disease progression in patients with liver cirrhosis].
Wu HQ; Zhao JJ; Li HW; Zhang Z
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):738-744. PubMed ID: 29108201
[No Abstract] [Full Text] [Related]
7. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
8. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
10. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
[TBL] [Abstract][Full Text] [Related]
11. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
14. Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.
Ippolito S; Di Dalmazi G; Pani F; Sabini E; Caturegli P
Thyroid; 2021 Dec; 31(12):1839-1849. PubMed ID: 34598661
[No Abstract] [Full Text] [Related]
15. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.
Lechner MG; Cheng MI; Patel AY; Hoang AT; Yakobian N; Astourian M; Pioso MS; Rodriguez ED; McCarthy EC; Hugo W; Angell TE; Drakaki A; Ribas A; Su MA
J Immunol; 2022 Aug; 209(4):696-709. PubMed ID: 35817515
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade.
Lavoie JM; Baichoo P; Chavez E; Nappi L; Khalaf D; Kollmannsberger CK; Chi KN; Weng A; Steidl C; Eigl BJ; Nissen M
Front Oncol; 2022; 12():973402. PubMed ID: 36176410
[TBL] [Abstract][Full Text] [Related]
17. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
18. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
Park BC; Narayanan S; Gavraldis A; Ye F; Fan R; Sullivan RJ; Boland G; Reynolds KL; Balko JM; Carlino MS; Long GV; Zubiri L; Menzies AM; Johnson DB
Oncoimmunology; 2023; 12(1):2188719. PubMed ID: 36926262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]